Objective The purpose of this studywas to evaluate the near efficacy and toxicity of oxaliplatin plus capecitabine regimen (XELOX) versus oxaliplatin plus fluorouracil/leucovorin (LV/5FU) regimen (FOLFOX4) in the treatmentofadvanced colorectal cancer . Methods 62 cases with metastatic and recurring colorectal cancer were enrolled into this study, 62 patients were randomly divided into (XELOX )A group 31 patients and( FOLFOX4 ) B group 31 patients respectively. metastatic organ include: liver32 paitients, lung19 paitients, lymph follicl、soft tissue、intestinal tract、appendix ovarii、bone、brain、glandula prostata and so on.Results All 62 caseswere available forobjective response. A group,the overall response ratewas48% (CR 3, PR 12), Themedian time to progression ( TTP) was 6.21months. B group,the overall response ratewas54.8% (CR 4, PR13), Themedian time to progression ( TTP) was 5.71months. The toxicitieswerewell tolerated,A group neutrocytopenia incidence rate12.9% was significanly lower than B group 45.2%(P<0.01);A group neurotoxicity incidence rate 3.23% was significanly lower than B group 58.1%(P<0.01);hand and foot syndrome in A group incidence rate 47.6% was more obvious than in B group 12.9% (P<0. 05),but gradeⅠ～Ⅱ. Conclusions The difference in response rate was not statistically significantbetween the two groups , well tolerated and effective in treatment of advanced colorectal cancer XELOX regimen may be safer than FOLFOX4 regimen, and Medication XELOX regimen may be convenienter than FOLFOX4 regimen.%目的 比较草酸铂联合希罗达方案(XELOX)与草酸铂联合FU/LV (FOLFOX4)方案治疗的晚期结直肠癌的近期疗效和毒副反应.方法 62例转移或复发晚期结直肠癌患者随机分为两组,草酸铂联合希罗达 (XELOX) A组31例,草酸铂联合FU/LV (FOLFOX4组)B组31例.转移部位包括:肝脏32例,肺脏19例, 淋巴结、软组织、肠道、附件、骨、脑、前列腺等.结果 两组患者各有31例可评价疗效.A组,CR3例,PR12例,有效率(CR+PR)48.4%,疾病进展时间(TTP)为6.21个月.B组CR4例PR13例,有效率(CR+PR)54.8%, TTP为5.71个月.A组中性粒细胞减少发生率12.9%,显著低于B组45.2%(P=0.005<0.01);A组神经毒性发生率16.13%显著低于B组58.1%(P=0.001<0.01);A组的手足综合症发生率(48.4%)明显高于B组12.9%(P=0.002<0.01),但程度较轻,主要为Ⅰ～Ⅱ度.结论 XELOX方案与FOLFOX4方案的疗效相近,但XELOX方案用药更为方便,安全性更好等优点.
展开▼
